Literature DB >> 19452318

Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia.

Margot Jak1, Rogier Mous, Ester B M Remmerswaal, René Spijker, Annelieke Jaspers, Adriana Yagüe, Eric Eldering, René A W Van Lier, Marinus H J Van Oers.   

Abstract

Recently, it has been described that patients with chronic lymphocytic leukemia (CLL) have increased numbers of regulatory T (T(reg)) cells. In the present study, we analysed the mechanism behind T(reg) cells expansion in CLL. Neither analysis of the T-cell receptor repertoire nor CD45 isoform expression of T(reg) cells from patients with CLL provided evidence for chronic (tumor) antigenic stimulation as a possible cause for T(reg) cells expansion in CLL. We found evidence however for increased formation of T(reg) cells via CD70 costimulation, because we observed that CD40 ligand activated CLL cells (which might be considered a model of lymph node CLL cells) strongly induced CD70-dependent formation of T(reg) cells. Reverse transcription-multiplex ligation-dependent probe amplification assay expression analysis of 34 apoptosis-regulating genes showed that in comparison with other CD4(+) T-cells, T(reg) cells from both healthy individuals (HD) and patients with CLL had a high expression of pro-apoptotic Noxa and a low expression of anti-apoptotic Bcl-2. Strikingly, Bcl-2 levels of T(reg) cells in patients with CLL were significantly higher than in HD. Finally, the different apoptotic profile resulted in differences at the functional level, because T(reg) cells from patients with CLL were more resistant to drug-induced apoptosis than T(reg) cells from HD. In conclusion, T(reg) cells in CLL may accumulate both by increased formation, facilitated by CD27-CD70 interaction in the lymph node proliferation centres, and decreased sensitivity to apoptosis because of a shifted Noxa-Bcl-2 balance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19452318     DOI: 10.1080/10428190902803677

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  36 in total

1.  The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Authors:  R Thijssen; J Ter Burg; G G W van Bochove; M F M de Rooij; A Kuil; M H Jansen; T W Kuijpers; J W Baars; A Virone-Oddos; M Spaargaren; C Egile; M H J van Oers; E Eldering; M J Kersten; A P Kater
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

2.  Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages.

Authors:  Paolo Giannoni; Gabriella Pietra; Giorgia Travaini; Rodolfo Quarto; Genti Shyti; Roberto Benelli; Laura Ottaggio; Maria Cristina Mingari; Simona Zupo; Giovanna Cutrona; Ivana Pierri; Enrico Balleari; Alessandra Pattarozzi; Marco Calvaruso; Claudio Tripodo; Manlio Ferrarini; Daniela de Totero
Journal:  Haematologica       Date:  2014-02-21       Impact factor: 9.941

Review 3.  Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells.

Authors:  Rajendra N Damle; Carlo Calissano; Nicholas Chiorazzi
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

4.  Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?

Authors:  Giovanni D'Arena; Vittorio Simeon; Fiorella D'Auria; Teodora Statuto; Paola Di Sanzo; Laura De Martino; Aurelio Marandino; Michele Sangiorgio; Pellegrino Musto; Vincenzo De Feo
Journal:  Am J Blood Res       Date:  2013-01-17

5.  Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.

Authors:  Rohtesh S Mehta; Antonio Di Stasi; Chitra Hosing; Nina Shah; Katayoun Rezvani; Amin Alousi; Susan O'Brien; William Wierda; Michael Keating; Elizabeth J Shpall
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-12-27

6.  Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.

Authors:  Priyanka Banerjee; Ronghua Zhang; Cristina Ivan; Giovanni Galletti; Karen Clise-Dwyer; Federica Barbaglio; Lydia Scarfò; Miguel Aracil; Christian Klein; William Wierda; William Plunkett; Federico Caligaris-Cappio; Varsha Gandhi; Michael J Keating; Maria Teresa S Bertilaccio
Journal:  Cancer Immunol Res       Date:  2019-09-17       Impact factor: 11.151

7.  HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.

Authors:  Annika Nelde; Daniel J Kowalewski; Linus Backert; Heiko Schuster; Jan-Ole Werner; Reinhild Klein; Oliver Kohlbacher; Lothar Kanz; Helmut R Salih; Hans-Georg Rammensee; Stefan Stevanović; Juliane S Walz
Journal:  Oncoimmunology       Date:  2018-02-14       Impact factor: 8.110

8.  Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia.

Authors:  Angélique Biancotto; Pradeep K Dagur; John C Fuchs; Adrian Wiestner; C Bruce Bagwell; J Philip McCoy
Journal:  Mod Pathol       Date:  2011-11-18       Impact factor: 7.842

9.  Terminally differentiated CD8+ T cells and CD57-FOXP3+CD8+ T cells are highly associated with the efficacy of immunotherapy using activated autologous lymphocytes.

Authors:  Junji Akagi; Hideo Baba; Teruaki Sekine; Kenji Ogawa
Journal:  Oncol Lett       Date:  2018-04-17       Impact factor: 2.967

Review 10.  Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions.

Authors:  Farhad Jadidi-Niaragh; Ghasem Ghalamfarsa; Mehdi Yousefi; Mina Hajifaraj Tabrizi; Fazel Shokri
Journal:  Tumour Biol       Date:  2013-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.